The European Centre for Disease Prevention and Control (ECDC) is an agency of the European Union (EU) whose mission is to strengthen Europe's defences against infectious diseases. It covers a wide spectrum of activities, such as: surveillance, epidemic intelligence, response, scientific advice, microbiology, preparedness, public health training, international relations, health communication, and the scientific journal Eurosurveillance.The centre was established in 2004 and is headquartered in Solna, Sweden.
In 2023 the European Centre for Disease Prevention and Control (ECDC) launched RespiCast, the first European Respiratory Diseases Forecasting Hub, to provide probabilistic forecasts for influenza-like illness (ILI) and acute respiratory infection (ARI) incidence across 26 European countries. During the 2023/24 and 2024/25 winter seasons, RespiCast collected one- to four-week-ahead forecasts from multiple models contributed by different international teams and combined them into an ensemble. Our analysis shows that, when evaluated using the weighted interval score (WIS) and the absolute error (AE), the ensemble consistently outperformed the baseline model (defined as a persistence model that projects the last observed value forward) as well as individual models across most countries and forecasting rounds for both ILI and ARI incidence in the two seasons. Analysis of ensemble coverage (defined as the proportion of times observed values fall within the specified prediction intervals) indicated that forecast prediction intervals were reliable, although a general overconfidence trend (i.e., prediction intervals that are too narrow) was observed, particularly in specific countries. The relative performance of the ensemble declined in certain weeks, likely due to reduced participation from modelling teams, epidemic dynamics, higher data noise, and reporting delays. Forecast scores varied across countries, with some exhibiting consistently higher relative errors than others. Overall, the findings highlight the strengths of ensemble approaches in improving the accuracy and reliability of epidemiological forecasts while identifying areas for improvement, such as managing overconfidence and addressing variability in performance across countries and over time.
Hepatitis C virus (HCV) remains a major public health concern worldwide. Spain has implemented large-scale direct-acting antiviral (DAA) treatment programs, yet the prevalence of active HCV infection (aHCV) and its trends over time remain incompletely characterised. We applied Bayesian multiparameter evidence synthesis (MPES) to estimate the prevalence of aHCV in Spain in 2022 and its change from 2019 to 2022. The Spanish population aged 15-79 years was stratified into four non-overlapping risk groups: current people who inject drugs (PWID), ex-PWID, gay-bisexual and other men who have sex with men (GBMSM) engaging in chemsex (GBMSMchem), and the general population. Data sources included, among others, national seroprevalence surveys, behavioural studies, national databases, and clinical records on DAA treatment outcomes. The estimated overall aHCV prevalence in Spain in 2022 was 0.14% (95% Credible Interval: 0.05%-0.27%), corresponding to approximately 54,500 individuals. Prevalence was highest among current PWID (12.5%) and GBMSMchem (8.4%). Compared to 2019, the total number of aHCV cases declined by ~20,000, largely attributable to DAA treatment. Among the general population, 29.4% of aHCV cases remained undiagnosed, with the highest prevalence in individuals aged 50-59 (0.25%) and 60-69 (0.16%) years. Spain has made substantial progress towards HCV elimination, but key populations such as PWID and GBMSMchem remain at high risk. Targeted interventions, including expanded harm reduction services and accessible HCV testing and treatment, are essential to achieving the World Health Organization (WHO) elimination targets by 2030.
BACKGROUND:We conducted a multicenter test-negative study to estimate vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza in primary care, Europe, 2024/25. RESEARCH DESIGN AND METHODS:Specimens were collected from patients with acute respiratory infection. All or a random sample of viruses were sequenced. VE was (1-odds ratio) × 100, adjusted for confounders. RESULTS:We included 7275 cases and 17,516 controls (weeks 40-2024-18-2025). The overall VE was 46% (95% CI: 40-52), lowest in adults ≥65 years at 28% (95% CI: 12-42). VE against influenza A(H1N1)pdm09 was 30% (95% CI: 19-40); ranging 16-34% by age and vaccination target group. Most (88%) circulating clades were 5a.2a, distinct from the vaccine clade. VE was 28% (95% CI: 7-45) against 5a.2a (C.1.9), and 6% (95% CI: -62-45) against the vaccine-matched clade 5a.2a.1 (D). VE against influenza A(H3N2) was 38% (95% CI: 26-49); ranging 20-66% by age and target group. Circulating viruses belonged to the vaccine clade 2a.3a.1, with 88% subclade (J.2). VE against influenza B was 76% (95% CI: 69-81); ranging 70-80% by age and target group; all viruses belonged to the vaccine clade V1A.3a.2, with diverse subclades. CONCLUSIONS:Influenza vaccination protected approximately one in two vaccinated individuals against medically attended infection in primary care in Europe, 2024/25, varying by (sub)type and age.
Background: Resources to respond to emerging and re-emerging infectious disease emergencies are limited. Aim: To support preparedness planning and resource allocation, a prioritisation methodology was applied to rank epidemic-prone diseases in Eastern Africa. Setting: The study took place in the eastern region of Africa representing 14 member states. Methods: A multi-criteria decision analysis (MCDA) combined with a modified Delphi approach, adapted from the Africa Centres for Disease Control and Prevention (CDC’s) continental prioritisation framework was employed. A planning team of epidemiologists and infectious disease experts designed the exercise, implemented through a three-day workshop in Comoros from 9 May 2023 to 11 May 2023. The workshop convened 43 experts from Eastern Africa member states and partner organisations to rank diseases. Participants assessed each disease against 19 predefined criteria, grouped into four overarching domains: risk trajectory, epidemic potential, disease severity, and preparedness and medical countermeasures. Overall risk was calculated as the product of risk trajectory, epidemic potential, and disease severity. Results: Twenty-eight experts (88%, 28 of the eligible participants, n = 32) prioritised 22 potential epidemic-prone diseases. The top 10 were Ebola virus disease (risk = 12.7), Marburg virus disease (11.8), cholera (11.1), coronavirus disease 2019 (COVID-19) (9.9), influenza (8.9), measles (8.6), yellow fever (8.5), Crimean-Congo haemorrhagic fever (8.2), malaria (8.0) and Rift Valley fever (7.9). The unknown disease, defined as one caused by a hypothetical novel pathogen (often referred to as ‘Disease X’), Crimean-Congo haemorrhagic fever, Rift Valley fever and mpox received the lowest preparedness rating. Conclusion: Ebola virus disease (EVD), Marburg virus disease (MVD) and cholera ranked highest in risk, while unknown disease and zoonoses showed the lowest preparedness. Contribution: Amid current funding constraints, these findings provide evidence to guide Africa CDC and partners in strengthening emergency preparedness and response in Eastern Africa, highlighting priority diseases while underscoring the need for further analysis of capacity gaps.
IntroductionCarbapenem-resistant (CR)-Enterobacterales are a serious threat to public health worldwide. However, there are limited surveillance data on the molecular epidemiology of CR-Escherichia coli. To address this need, the European Centre for Disease Prevention and Control (ECDC) investigated the molecular epidemiology of CR-E. coli in the carbapenem- and/or colistin-resistant Enterobacterales (CCRE) survey launched in 2019, involving 37 European countries, including Italy.MethodsIn 2019, 46 acute-care hospitals in Italy were enrolled to collect the first 10 non-duplicated consecutive isolates of carbapenem non-susceptible Klebsiella pneumoniae specie complex or E. coli isolates and 10 carbapenem-susceptible comparator isolates of the same species. Each isolate was subjected to antibiotic susceptibility testing. WGS analysis was performed using Illumina technology to determine the ST and to detect resistance genes, virulence factors, and plasmid content.ResultsA total of 61 E. coli isolates were collected from 17 hospitals: 17 CR-E. coli isolates (from urine, 41.2%, and blood, 23.5%) and 44 carbapenem-susceptible (CS)-isolates (from blood, 43.2%, and urine, 38.6%). All the CR-E. coli isolates were resistant to amoxicillin/clavulanic acid, cefepime, ceftazidime and piperacillin/tazobactam; three were resistant to ceftazidime/avibactam and all were susceptible to amikacin and tigecycline. MLST analysis showed the presence of unrelated lineages: CR-E. coli isolates belonged to 8 different STs, with ST131 predominant (58.8%). All the CR-E. coli isolates carried one carbapenemase: KPC-3 (10 isolates), KPC-2 (three), NDM-5 (two), VIM-1 and OXA-181 (one each). Among CS-E. coli isolates, the highest resistance rates were observed for amoxicillin/clavulanic acid (36.4%) followed by ciprofloxacin, and trimethoprim/sulfamethoxazole, and ST131, carrying CTX-M-15, was the predominant clone.DiscussionCR-E. coli clones from infection showed a heterogeneous genetic background, ST131 being the most frequent. KPC was the most common carbapenemase but the presence of E. coli isolates carrying NDM-5 is worrisome, as it results in resistance to several novel beta-lactam-beta-lactamase combinations. Our study underlines the importance of genomic surveillance to monitor and prevent the spread of high-risk clones causing difficult-to-treat infections.